- Trial statusAnalysis
- Study email email@example.com
- Chief InvestigatorCarlo Palmieri
- SponsorImperial College London
A phase II, open label, preoperative study to assess the efficacy of the novel steroid sulfatase inhibitor Irosustat in postmenopausal women with early oestrogen receptor positive breast cancer.
Design and Objective
Primary Objective: To assess changes in [18F] fluorothymidine (FLT) uptake using Positron Emission Tomography (PET) following 2 weeks of Irosustat treatment in patients with early, treatment naïve, oestrogen receptor positive (ER +ve) breast cancer.
Key inclusion criteria
18 years of age or older Postmenopausal Histologically confirmed ER +ve breast cancer (Allred >3). Tumour measuring ≥15mm in longest diameter ECOG performance status 0, 1 or 2 Adequate bone marrow, renal and liver function No evidence of bleeding diathesis Written informed consent to participate in the trial and to donate tissue and blood samples